Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease

Journal of Internal Medicine

Volumn 262, Issue 2, 2007, Pages 244-253

  Bleie, O ^a,b   Semb, A G ^c   Grundt, H ^b,d   Nordrehaug, J E ^a,b   Vollset, S E ^e   Ueland, P M ^b   Nilsen, D W T ^b,d   Bakken, A M ^a   Refsum, H ^f,g   Nygard O K ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c DIAKONHJEMMET HOSPITAL   (Norway)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e Department of Public Health and Primary Health Care ^*

^f UNIVERSITY OF OSLO   (Norway)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atherosclerosis; B vitamins; Homocysteine; Inflammation; Neopterin; Soluble CD40 ligand

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEOPTERIN; PLACEBO; PYRIDOXINE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CD40 LIGAND; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPTERIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 34447626134     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01810.x     Document Type: Article

References (40)

1. Nygard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM. Total homocysteine and cardiovascular disease. J Intern Med 1999 246 : 425 54.
2. Rasouli ML, Nasir K, Blumenthal RS, Park R, Aziz DC, Budoff MJ. Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis 2005 181 : 159 65.
3. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000 102 : 2479 83.
4. Riba R, Nicolaou A, Troxler M, Homer-Vaniasinkam S, Naseem K. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis 2004 175 : 69 75.
5. Schroecksnadel K, Frick B, Winkler C, Leblhuber F, Wirleitner B, Fuchs D. Hyperhomocysteinemia and immune activation. Clin Chem Lab Med 2003 41 : 1438 43.
6. Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med 2005 5 : 215 22.
7. Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004 291 : 565 75.
8. Bonaa KH, Njolstad I, Ueland PM et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006 354 : 1578 88.
9. Lonn E, Yusuf S, Arnold MJ et al. Homocysteine lowering with folic acid and b vitamins in vascular disease. N Engl J Med 2006 354 : 1567 77.
10. Zoungas S, McGrath BP, Branley P et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006 47 : 1108 16.
11. Lange H, Suryapranata H, De Luca G et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004 350 : 2673 81.
12. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001 345 : 1593 600.
13. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006 83 : 456S 60.
14. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004 116 (6, Suppl. 1 9 16.
15. Aukrust P, Muller F, Ueland T et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999 100 : 614 20.
16. Aukrust P, Yndestad A, Waehre T, Gullestad L, Halvorsen B, Damas JK. Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Rev Cardiovasc Ther 2005 3 : 1111 24.
17. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002 3 : 175 87.
18. Gurfinkel EP, Scirica BM, Bozovich G, Macchia A, Manos E, Mautner B. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol 1999 83 : 515 8.
19. Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol 2000 35 : 956 62.
20. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004 110 : 1747 53.
21. Widner B, Enzinger C, Laich A, Wirleitner B, Fuchs D. Hyperhomocysteinemia, pteridines and oxidative stress. Curr Drug Metab 2002 3 : 225 32.
22. Bleie O, Refsum H, Ueland PM et al. Changes in basal and postmethionine load concentrations of total homocysteine and cystathionine after B vitamin intervention. Am J Clin Nutr 2004 80 : 641 8.
23. Husek P. Chloroformates in gas chromatography as general purpose derivatizing agents. J Chromatogr B Biomed Sci Appl 1998 717 : 57 91.
24. O'Broin S, Kelleher B. Microbiological assay on microtitre plates of folate in serum and red cells. J Clin Pathol 1992 45 : 344 7.
25. Kelleher BP, Walshe KG, Scott JM, O'Broin SD. Microbiological assay for vitamin B12 with use of a colistin-sulfate-resistant organism. Clin Chem 1987 33 : 52 4.
26. Bor MV, Refsum H, Bisp MR et al. Plasma vitamin B6 vitamers before and after oral vitamin B6 treatment: a randomized placebo-controlled study. Clin Chem 2003 49 : 155 61.
27. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999 130 : 461 70.
28. Holven KB, Aukrust P, Retterstol K et al. Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects. Scand J Clin Lab Invest 2006 66 : 45 54.
29. Robinson K, Arheart K, Refsum H et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998 97 : 437 43.
30. Erren M, Reinecke H, Junker R et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999 19 : 2355 63.
31. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 2004 37 : 684 7.
32. Gottsater A, Forsblad J, Mattiasson I, Lindgarde F. Decreasing plasma endothelin-1 and unchanged plasma neopterin during folate supplementation in hyperhomocysteinemia. Int Angiol 2002 21 : 158 64.
33. Frick B, Gruber B, Schroecksnadel K, Leblhuber F, Fuchs D. Homocysteine but not neopterin declines in demented patients on B vitamins. J Neural Transm 2006 V113 : 1815 9.
34. Taniguchi A, Fukushima M, Nakai Y et al. Soluble tumor necrosis factor receptor 1. Is strongly and independently associated with serum homocysteine in nonobese Japanese Type 2 diabetic patients. Diabetes Care 2006 29 : 949 a.
35. Dusitanond P, Eikelboom JW, Hankey GJ et al. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial. Stroke 2005 36 : 144 6.
36. van Aken BE, Jansen J, van Deventer SJ, Reitsma PH. Elevated levels of homocysteine increase IL-6 production in monocytic Mono Mac 6 cells. Blood Coagul Fibrinolysis 2000 11 : 159 64.
37. Dalal S, Parkin SM, Homer-Vanniasinkam S, Nicolaou A. Effect of homocysteine on cytokine production by human endothelial cells and monocytes. Ann Clin Biochem 2003 40 (Pt 5 534 41.
38. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000 101 : 1767 72.
39. Araki A, Hosoi T, Orimo H, Ito H. Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes. Metabolism 2005 54 : 809 14.
40. Clarke R, Lewington S, Sherliker P, Armitage J. Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. Curr Opin Clin Nutr Metab Care 2007 10 : 32 9.